-DOCSTART- -X- O
Combination -X- _ B-Intervention
antiretroviral -X- _ I-Intervention
therapy -X- _ I-Intervention
( -X- _ I-Intervention
ART -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
highly -X- _ O
effective -X- _ O
in -X- _ O
controlling -X- _ O
human -X- _ O
immunodeficiency -X- _ O
virus -X- _ O
( -X- _ O
HIV -X- _ O
) -X- _ O
-1 -X- _ O
but -X- _ O
requires -X- _ O
lifelong -X- _ O
medication -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
existence -X- _ O
of -X- _ O
a -X- _ O
latent -X- _ O
viral -X- _ O
reservoir -X- _ O
( -X- _ O
1,2 -X- _ O
) -X- _ O
. -X- _ O
Potent -X- _ O
broadly -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
( -X- _ O
bNAbs -X- _ O
) -X- _ O
represent -X- _ O
a -X- _ O
potential -X- _ O
alternative -X- _ O
or -X- _ O
adjuvant -X- _ O
to -X- _ O
ART. -X- _ O
In -X- _ O
addition -X- _ O
to -X- _ O
suppressing -X- _ O
viremia -X- _ O
, -X- _ O
bNAbs -X- _ O
may -X- _ O
have -X- _ O
T -X- _ O
cell -X- _ O
immunomodulatory -X- _ O
effects -X- _ O
as -X- _ O
seen -X- _ O
for -X- _ O
other -X- _ O
forms -X- _ O
of -X- _ O
immunotherapy -X- _ O
( -X- _ O
3 -X- _ O
) -X- _ O
. -X- _ O
However -X- _ O
, -X- _ O
this -X- _ O
has -X- _ O
not -X- _ O
been -X- _ O
established -X- _ O
in -X- _ O
individuals -X- _ O
who -X- _ O
are -X- _ O
infected -X- _ O
with -X- _ O
HIV-1. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
document -X- _ O
increased -X- _ O
HIV-1 -X- _ B-Outcome
Gag-specific -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
peripheral -X- _ I-Outcome
blood -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
nine -X- _ I-Outcome
study -X- _ I-Outcome
participants -X- _ I-Outcome
who -X- _ I-Outcome
were -X- _ I-Outcome
infected -X- _ I-Outcome
with -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
with -X- _ I-Outcome
suppressed -X- _ I-Outcome
blood -X- _ I-Outcome
viremia -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
receiving -X- _ I-Outcome
bNAb -X- _ I-Outcome
therapy -X- _ I-Outcome
during -X- _ I-Outcome
ART -X- _ I-Outcome
interruption -X- _ I-Outcome
( -X- _ I-Outcome
4 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Increased -X- _ I-Outcome
CD4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
eight -X- _ I-Outcome
individuals. -X- _ I-Outcome
The -X- _ I-Outcome
increased -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
were -X- _ I-Outcome
due -X- _ I-Outcome
both -X- _ I-Outcome
to -X- _ I-Outcome
newly -X- _ I-Outcome
detectable -X- _ I-Outcome
reactivity -X- _ I-Outcome
to -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
Gag -X- _ I-Outcome
epitopes -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
expansion -X- _ I-Outcome
of -X- _ I-Outcome
pre-existing -X- _ I-Outcome
measurable -X- _ I-Outcome
responses. -X- _ I-Outcome
These -X- _ O
data -X- _ O
demonstrate -X- _ O
that -X- _ O
bNAb -X- _ O
therapy -X- _ O
during -X- _ O
ART -X- _ O
interruption -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
enhanced -X- _ B-Outcome
HIV-1-specific -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses. -X- _ I-Outcome
Whether -X- _ O
these -X- _ O
augmented -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
can -X- _ O
contribute -X- _ O
to -X- _ O
bNAb-mediated -X- _ O
viral -X- _ O
control -X- _ O
remains -X- _ O
to -X- _ O
be -X- _ O
determined -X- _ O
. -X- _ O

